Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 21, 2008 - Issue 4
Submit an article Journal homepage
104
Views
10
CrossRef citations to date
0
Altmetric
Articles

Pulmonary Invasive Mucormycosis in a Patient with Secondary Iron Overload Following Deferoxamine Therapy

Hector M. Reyes
, MD,
Eric J. Tingle
, MD,
Andrew Z. Fenves
, MD,
Jennifer Spiegel
, MD &
Elizabeth C. BurtonCorrespondence[email protected]
, MD
Pages 378-381 | Published online: 11 Dec 2017

  • Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004;10 (Suppl 1): 31–47.
  • Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GE, Vandenberghe P, Boogaerts MA. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999;24 (3): 307–312.
  • Fenves AZ. The interrelationship between iron and infectious diseases. Proc (Bayl Univ Med Cent) 1990;3 (2): 35–37.
  • Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989;36 (6): 1061–1068.
  • Verdonck A, Boelaert JR, Gordts B, et al. Effect of feroxamine on the growth of Rizopus. Abstracts of the 91st General Meeting of the American Society of Microbiology, Dallas, Texas, May 5–9, 1991 (abstr F-68).
  • Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia 1990;110 (2): 87–91.
  • Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991;18 (6): 660–667.
  • Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, Van Landuyt HW, Schneider YJ. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91 (5): 1979–1086.
  • Sugar AM. Mucormycosis. Clin Infect Dis 1992;14 (Suppl 1): S126–S129.
  • Verpooten GA, D'Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 1992;7 (9): 931–938.
  • Brown AE, Cicogna C, Armstrong D. Mucormycosis in patients with cancer. Infect Med 1994;11: 562–563.
  • Mucormycosis. Ann Intern Med 1980;93: 93–108.
  • Daly AL, Velazquez LA, Bradley SF, Kauffman CA. Mucormycosis: association with deferoxamine therapy. Am J Med 1989;87 (4): 468–471.
  • Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994;45 (3): 667–671.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.